Cervical squamous cell carcinoma
MONDO:0006143A squamous cell carcinoma arising from the cervical epithelium. It usually evolves from a precancerous cervical lesion. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors for cervical squamous cell carcinoma. The following histologic patterns have been described: conventional squamous cell carcinoma, papillary squamous cell carcinoma, transitional cell carcinoma, lymphoepithelioma-like carcinoma, verrucous carcinoma, condylomatous carcinoma and spindle cell carcinoma. Survival is most closely related to the stage of disease at the time of diagnosis.
Also known as: cervical squamous cell cancer, cervical squamous cell carcinoma, cervix squamous cell carcinoma, cervix uteri squamous cell carcinoma, squamous cell carcinoma of cervix, squamous cell carcinoma of cervix uteri, squamous cell carcinoma of the cervix, squamous cell carcinoma of the cervix uteri
2875 clinical trials for this condition and its sub-types, 36 tagged with Cervical squamous cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Cervical squamous cell carcinoma
-
Cervical adenosquamous carcinoma 16 trials
1 sub-type
-
Cervical basaloid carcinoma 0 trials
-
Cervical verrucous carcinoma 0 trials
-
New cancer drug BBI-355 trial halted early – what we know
Disease control Stopped earlyThis early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…
Phase 1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a Two-Pronged attack shrink Hard-to-Treat cancers?
Disease control Stopped earlyThis trial tests whether an experimental drug called XNW5004, which blocks a protein that helps cancer grow, can boost the effects of the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have stopped responding to standard treatments. The study inc…
Phase 1/2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Gentler surgery for cervical cancer shows promise, study halted early
Disease control Stopped earlyThis study looked at whether a less invasive surgery (conservative surgery) could safely treat women with early-stage, low-risk cervical cancer. The goal was to see if this approach causes fewer side effects and helps recovery. The study included 137 women with stage IA2 or IB1 c…
Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC